Evaluation of Mean Platelet Volume and Systemic Inflammatory Response Index (SIRI) in Patients of Acute Coronary Syndrome

NCT07149883 | Not Yet Recruiting

• 1 other identifier: MPV and SIRI in of ACS
• Study Type: observational
• Target: 300
• Locations: 0 countries
• Sites: N/A

Brief Summary

To assess the diagnostic and prognostic significance of MPV and SIRI in patients presenting with acute coronary syndrome.(STEMI/NSTEMI/UN STABLE ANGINA)

Conditions

Coronary Artery Disease

Outcome Measures

Primary Outcomes (1)

• To assess the diagnostic and prognostic significance of MPV and SIRI in patients presenting with acute coronary syndrome.(STEMI/NSTEMI/UN STABLE ANGINA)

  Evaluation of mean platelet volume and systemic inflammatory response index (SIRI) in patients of acute coronary syndrome

  Baseline

Secondary Outcomes (1)

• To assess the diagnostic and prognostic significance of MPV and SIRI in patients presenting with acute coronary syndrome.(STEMI/NSTEMI/UN STABLE ANGINA

  Baseline

Interventions

Complete blood count OTHER

Complete blood count

ECHO DEVICE

device that used to evaluate the cardiac function

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Acute coronary syndrome (ACS), which includes unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI), is a leading cause of hospitalization and death globally【1】. The pathophysiology of ACS involves plaque rupture, platelet activation, thrombus formation, and a significant inflammatory component【2】. Early diagnosis and accurate risk stratification are critical for improving patient outcomes and guiding therapy. Mean Platelet Volume (MPV) is a simple, cost-effective parameter obtained from the complete blood count. It reflects platelet size and activity-larger platelets are more reactive and thrombogenic. Studies have demonstrated that MPV is elevated in patients with ACS and may correlate with infarct size and poor prognosis【3,4】. The systemic inflammatory response plays a pivotal role in the destabilization of atherosclerotic plaques. Recently, novel inflammatory indices such as the Systemic Inflammatory Response Index (SIRI)-

You may qualify if:

• Patients ≥ 18 years old.
• Diagnosed with acute coronary syndrome (unstable angina, NSTEMI, STEMI).
• Admission within 24 hours of symptom onset.

You may not qualify if:

• o Active infection or chronic inflammatory diseases.
• Known hematological disorders or malignancy.
• Chronic liver or renal failure.
• Recent surgery or trauma (\< 1 month).
• Patients with rheumatic heart disease
• Patient refusal

Sponsors & Collaborators

• Assiut University: lead

Related Publications (2)

• Libby P. Inflammation in atherosclerosis. Nature. 2002 Dec 19-26;420(6917):868-74. doi: 10.1038/nature01323.

  PMID: 12490960 BACKGROUND

• Anderson JL, Morrow DA. Acute Myocardial Infarction. N Engl J Med. 2017 May 25;376(21):2053-2064. doi: 10.1056/NEJMra1606915. No abstract available.

  PMID: 28538121 BACKGROUND

MeSH Terms

Conditions

Coronary Artery Disease

Interventions

Blood Cell Count

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Intervention Hierarchy (Ancestors)

Cell Count; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Hematologic Tests; Investigative Techniques; Cell Physiological Phenomena; Blood Physiological Phenomena; Circulatory and Respiratory Physiological Phenomena

Study Officials

• Ghada Hassan, Professor

  Assuit university hospital

  STUDY DIRECTOR

• Hanan Sharaf, Professor

  Assuit university hospital

  STUDY DIRECTOR

Central Study Contacts

Asmaa Salama ahmed omar, Resident doctor

CONTACT

+01067687469; asmaasalamaahmed4@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: August 24, 2025
• First Posted: September 2, 2025
• Study Start: September 20, 2025
• Primary Completion (Estimated): September 20, 2026
• Study Completion (Estimated): October 20, 2026
• Last Updated: September 2, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share